Research Paper Volume 15, Issue 9 pp 3690—3714
MGME1 associates with poor prognosis and is vital for cell proliferation in lower-grade glioma
Figure 8. Different responses to chemotherapy of the low-MGME1 and high-MGME1 subtypes in the TCGA dataset. (A–D) the PI3K/AKT inhibitors: TGX221 (A), ZSTK474 (B), AS605240 (C), and A-443654 (D). (E, F) the MAPK inhibitors: TAK-715 (E) and NG-25 (F). NF kappaB inhibitor: bortezomib (G). DNA replication inhibitor: Etoposide (H).